Pfizer Pays Isis Pharma and 3 Dow Movers Making Market Waves

The Walt Disney Company’s (NYSE:DIS) Wreck-It Ralph is expected to open at between $45 million and $50 million this weekend, say pre-release surveys, but its studio and theater executives are unsure as to what impact the hurricane might have on attendance, according to The Los Angeles Times.

General Electric Company (NYSE:GE) executives for the senior housing and care industries are confident as to their performance during the next 12 months, says a survey of industry executives released Friday by GE Capital Healthcare Financial Services. Some 77 percent of respondents referred to stronger performance expectations for the next 12 months compared to 2011 and 22 percent anticipated similar results year-over-year.

Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.

JPMorgan Chase & Co. (NYSE:JPM), HSBC Holdings (NYSE:HBC), Citigroup (NYSE:C), and Deutsche Bank (NYSE:DB) were named by the Financial Stability Board as the four banks most central to the system and it was recommended that those four should be subject to a capital surcharge of 2.5 percent above the statutory minimums set in “Basel III,” according to the Wall Street Journal. The Board coordinates the world regulatory response to the financial crisis on behalf of the Group of 20, and said that 24 addirional banks on its list should be subjected to lighter surcharges of between 1 and 2 percent above the capital equivalent of 7 percent of risk-weighted assets mandated by Basel III rules.

Pfizer (NYSE:PFE) will pay a $1.25 million contingent payment to Isis Pharmaceuticals (NASDAQ:ISIS), triggered by the former’s decision to advance EXC 001 into a Phase 2 study. Last year, Isis received $4.4 million for its equity ownership of Excaliard from Pfizer’s purchase of Excaliard Pharmaceuticals and, except for the $1.25 million, is eligible to receive $8.35 million more in contingent payments upon the achievement of various milestones linked with the clinical and commercial progress of EXC 001, also referred to as PF-06473871. Additionally, Isis remains eligible for milestone and royalty payments under its licensing agreement with Excaliard for EXC 001.

Don’t Miss: Here’s Why Pfizer Misses Lipitor.